RESUMEN
Intravenous (i.v.) bolus administration of xylazine (XYL) (0.5 mg/kg) immediately followed by a continuous rate infusion (CRI) of 1 mg kg-1 hr-1 for 2, 4, and 6 hr produced immediate sedation, which lasted throughout the duration of the CRI. Heart rate decreased and blood pressure increased significantly (p > .05) in all horses during the first 15 min of infusion, both returned to and then remained at baseline during the duration of the infusion. Compartmental models were used to investigate the pharmacokinetics of XYL administration. Plasma concentration-time curves following bolus and CRI were best described by a one-compartment model. No differences were found between pharmacokinetic estimates of the CRIs for the fractional elimination rate constant (Ke ), half-life (t1/2e ), volume of distribution (Vd ), and clearance (Cl). Median and range were 0.42 (0.15-0.97)/hr, 1.68 (0.87-4.52) hr, 5.85 (2.10-19.34) L/kg, and 28.7 (19.6-39.5) ml min-1 kg-1 , respectively. Significant differences were seen for area under the curve ( AUC 0 ∞ ) (p < .0002) and maximum concentration (Cmax ) (p < .04). This indicates that with increasing duration of infusion, XYL may not accumulate in a clinically relevant way and hence no adjustments are required in a longer XYL CRI to maintain a constant level of sedation and a rapid recovery.
Asunto(s)
Caballos/metabolismo , Hipnóticos y Sedantes/farmacocinética , Xilazina/farmacocinética , Animales , Área Bajo la Curva , Estudios Cruzados , Esquema de Medicación , Femenino , Semivida , Caballos/sangre , Hipnóticos y Sedantes/sangre , Inyecciones Intravenosas , Masculino , Xilazina/sangreRESUMEN
This study determined the pharmacokinetics and compared the clinical effects of xylazine and dexmedetomidine in horses recovering from isoflurane anesthesia. Six healthy horses aged 8.5 ± 3 years and weighing 462 ± 50 kg were anesthetized with isoflurane for 2 hr under standard conditions on two occasions one-week apart. In recovery, horses received 200 µg/kg xylazine or 0.875 µg/kg dexmedetomidine intravenously and were allowed to recover without assistance. These doses were selected because they have been used for postanesthetic sedation in clinical and research studies. Serial venous blood samples were collected for quantification of xylazine and dexmedetomidine, and the pharmacokinetic parameters were calculated. Two individuals blinded to treatment identity evaluated recovery quality with a visual analog scale. Times to stand were recorded. Results (mean ± SD) were compared using paired t tests or Wilcoxon signed-ranked test with p < .05 considered significant. Elimination half-lives (62.7 ± 21.8 and 30.1 ± 8 min for xylazine and dexmedetomidine, respectively) and steady-state volumes of distribution (215 ± 123 and 744 ± 403 ml/kg) were significantly different between xylazine and dexmedetomidine, whereas clearances (21.1 ± 17.3 and 48.6 ± 28.1 ml/minute/kg), times to stand (47 ± 24 and 53 ± 12 min) and recovery quality (51 ± 24 and 61 ± 22 mm VAS) were not significantly different. When used for postanesthetic sedation following isoflurane anesthesia in healthy horses, dexmedetomidine displays faster plasma kinetics but is not associated with faster recoveries compared to xylazine.
Asunto(s)
Analgésicos/farmacocinética , Periodo de Recuperación de la Anestesia , Dexmedetomidina/farmacocinética , Caballos/sangre , Isoflurano/farmacología , Xilazina/farmacocinética , Analgésicos/administración & dosificación , Analgésicos/farmacología , Anestésicos por Inhalación/administración & dosificación , Anestésicos por Inhalación/farmacocinética , Anestésicos por Inhalación/farmacología , Animales , Estudios Cruzados , Dexmedetomidina/administración & dosificación , Dexmedetomidina/farmacología , Femenino , Hipnóticos y Sedantes/administración & dosificación , Hipnóticos y Sedantes/farmacocinética , Masculino , Xilazina/administración & dosificación , Xilazina/farmacologíaRESUMEN
Xylazine is widely used worldwide as a short-acting sedative in general equine and racing practice. In the UK, although it has a legitimate use during training, equine anti-doping rules state it is a prohibited substance on race day. The aim of the study was to produce a detection time (DT) to better inform European veterinary surgeons so that xylazine can be used appropriately under regulatory rules. Previous publications have various limitations pertaining to analysis method, particularly for plasma and limited length of time of sample collection. In this study, pharmacokinetic data were produced for xylazine and 4-OH-xylazine in equine urine and plasma following a single intravenous xylazine dose of 0.4 mg/kg to six Thoroughbred horses. Pharmacokinetic parameters were generated from a 3-compartmental model with clearance = 15.8 ± 4.88 ml min-1 kg-1 , Vss = 1.44 ± 0.38 L/kg, terminal half-life = 29.8 ± 12.7 hr and a DT determined at 71 hr for the administration of xylazine (Chanazine® ) in plasma and urine. Urine screening should aim to detect the 4-OH-xylazine metabolite, which can act as an indicator for the xylazine plasma concentration. A DT of 72 hr has been agreed by the European Horserace Scientific Liaison Committee, to be implemented in June 2019.
Asunto(s)
Analgésicos/farmacocinética , Caballos/sangre , Xilazina/farmacocinética , Analgésicos/administración & dosificación , Animales , Área Bajo la Curva , Femenino , Semivida , Masculino , Xilazina/administración & dosificación , Xilazina/sangreRESUMEN
AIMS: To evaluate the pharmacokinetics of dexmedetomidine (DEX) administered I/V at a dose of 5â µg/kg bodyweight in dairy calves and to compare the sedative effects of anaesthetic protocols involving DEX and xylazine. METHODS: Nine dairy calves, aged 17-20 days, were treated with 5â µg/kg I/V dexmedetomidine. For pharmacokinetic evaluation, blood samples were collected over 12 hours and serum samples were analysed by high performance liquid chromatography-mass spectrometry. Another nine dairy calves, aged 16-20 days, were treated with 0.2â mg/kg I/V xylazine. After both treatments, heart rate, respiratory rate and rectal temperature were measured for 20 minutes. Sedation quality and recovery times were also assessed. RESULTS: The kinetics of DEX was best described by a two-compartment model. The distribution and elimination half-lives were 8.7 (SD 5.0) and 83.5 (SD 67.5) minutes, respectively. Mean maximum concentration and body clearance were 12.5 (SD 8.6) ng/mL and 27.9 (SD 13.1) mL/minute/kg, respectively; the mean volume of distribution at steady state was 2,170.8 (SD 1,657.5) mL/kg. A decrease in heart rate was observed after treatments with both DEX and xylazine. No differences in heart or respiration rate, or rectal temperature were observed between the two treatment groups. The onset of sedation occurred after 2.7 (SD 0.67) minutes for calves treated with DEX and 2.8 (SD 0.78) minutes for calves treated with xylazine, and was characterised by a similar degree of deep sedation and ease of handling of the calves. All recoveries were eventless, and no adverse reactions were noted. CONCLUSIONS AND CLINICAL RELEVANCE: Dexmedetomidine treatment resulted in a reliable and long lasting sedation in calves, a transient decrease in heart rate and no modification in respiratory rate or rectal temperature. The results were comparable to xylazine, the most popular alpha-2-agonist among bovine practitioners. The use of DEX in dairy calves for rapid procedures such as dehorning or castration could be suggested.
Asunto(s)
Sedación Consciente/veterinaria , Dexmedetomidina/farmacocinética , Hipnóticos y Sedantes/farmacocinética , Animales , Animales Recién Nacidos , Bovinos , Sedación Consciente/métodos , Dexmedetomidina/sangre , Dexmedetomidina/farmacología , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Hipnóticos y Sedantes/sangre , Hipnóticos y Sedantes/farmacología , Masculino , Frecuencia Respiratoria/efectos de los fármacos , Xilazina/farmacocinética , Xilazina/farmacologíaRESUMEN
While the cage refinement is a necessary step towards improving the welfare of research rats, increasing the complexity and surface area of the living space of an animal may have physiological impacts that need to be taken into consideration. In this study, ketamine (80 mg/kg) and xylazine (10 mg/kg) caused a short duration anesthesia that was significantly decreased in Sprague-Dawley rats housed in multilevel cages (MLC), compared to rats housed in standard cages (SDC). The withdrawal reflex, the palpebral reflexes and the time-to-sternal all occurred earlier in MLC housed rats, suggesting an effect of housing on the physiology of the rats. In addition, during anesthesia, cardiac frequencies were increased in animals housed in the smaller SDC. Respiratory frequencies, the blood oxygen saturation and rectal temperatures during anesthesia did not vary between conditions during the anesthesia. While xylazine pharmacokinetics were unchanged with caging conditions, the clearance and half-lives of ketamine and its metabolite, norketamine, were altered in the rats housed in MLC. Finally, while no difference was ultimately seen in rat body weights, isolated liver and adrenal gland weights were significantly lighter in rats housed in the MLC. Increasing cage sizes, while having a positive impact on wellbeing in rats, can alter anesthetic drug metabolism and thus modify anesthesia parameters and associated physiological processes.
Asunto(s)
Anestésicos Disociativos/farmacocinética , Vivienda para Animales , Hipnóticos y Sedantes/farmacocinética , Ketamina/farmacocinética , Ratas/fisiología , Xilazina/farmacocinética , Anestésicos Disociativos/farmacología , Animales , Semivida , Hipnóticos y Sedantes/farmacología , Ketamina/análogos & derivados , Ketamina/farmacología , Masculino , Ratas Sprague-Dawley , Reflejo/efectos de los fármacos , Organismos Libres de Patógenos Específicos , Xilazina/farmacologíaRESUMEN
The main objective of this study was to compare the physiological changes (withdrawal and corneal reflexes, respiratory and cardiac frequency, blood oxygen saturation, and rectal temperature) following intraperitoneal administration of ketamine (80 mg/kg) and xylazine (10 mg/kg) to 3-, 6-, 12- and 18-month-old male Sprague Dawley rats (n=6/age group). Plasma pharmacokinetics, liver metabolism, and blood biochemistry were examined for a limited number of animals to better explain anesthetic drug effects. Selected organs were collected for histopathology. The results for the withdrawal and corneal reflexes suggest a shorter duration and decreased depth of anesthesia with aging. Significant cardiac and respiratory depression, as well as decreased blood oxygen saturation, occurred in all age groups however, cardiac frequency was the most affected parameter with aging, since the 6-, 12-, and 18-month-old animals did not recuperate to normal values during recovery from anesthesia. Pharmacokinetic parameters (T1/2 and AUC) increased and drug clearance decreased with aging, which strongly suggests that drug exposure is associated with the physiological results. The findings for liver S9 fractions of 18-month-old rats compared with the other age groups suggest that following a normal ketamine anesthetic dose (80 mg/kg), drug metabolism is impaired, leading to a significant increase of drug exposure. In conclusion, age and related factors have a substantial effect on ketamine and xylazine availability, which is reflected by significant changes in pharmacokinetics and liver metabolism of these drugs, and this translates into shorter and less effective anesthesia with increasing age.
Asunto(s)
Envejecimiento/fisiología , Anestesia , Anestésicos/farmacocinética , Ketamina/farmacocinética , Hígado/metabolismo , Xilazina/farmacocinética , Anestésicos/administración & dosificación , Animales , Parpadeo , Frecuencia Cardíaca , Inyecciones Intraperitoneales , Ketamina/administración & dosificación , Masculino , Oxígeno/sangre , Ratas Sprague-Dawley , Respiración , Organismos Libres de Patógenos Específicos , Xilazina/administración & dosificaciónRESUMEN
In certain situations, an alternate route for parenteral drug administration in horses may be useful. The intra-osseous (IO) route may provide a safe alternative to the intravenous (i.v.) route for administration of sedatives to horses when the i.v. route is inaccessible or undesirable. Six adult horses were administered xylazine i.v. or IO in a block-randomized crossover design. For the i.v. trial, both jugular veins were catheterized, and one was used for xylazine administration, while the other was used for blood collection. For the IO trial, one jugular vein was catheterized for blood collection and an intra-osseous device was placed in the tuber coxae using a powered driver for xylazine administration. Heart rate, respiratory rate, and head position were measured, and concentration of sedation was assessed at various times up to 90 min. Xylazine concentrations were measured using high-performance liquid chromatography and noncompartmental analysis was performed. General linear mixed modeling and Wilcoxon signed-rank tests were used for statistical analysis, with P ≤ 0.05. There were no significant differences in heart rate, respiratory rate, head position, concentration of sedation, Cmax , Tmax , half-life, or AUC between the i.v. and the IO routes of drug administration. No complications were observed following placement of the intra-osseous device. Intra-osseous xylazine administration provides a useful option in emergent and other settings in which i.v. access is difficult or contraindicated.
Asunto(s)
Sedación Consciente/veterinaria , Caballos/metabolismo , Hipnóticos y Sedantes/farmacocinética , Xilazina/farmacocinética , Animales , Sedación Consciente/métodos , Estudios Cruzados , Frecuencia Cardíaca/efectos de los fármacos , Hipnóticos y Sedantes/administración & dosificación , Hipnóticos y Sedantes/sangre , Hipnóticos y Sedantes/farmacología , Infusiones Intraóseas/veterinaria , Infusiones Intravenosas/veterinaria , Frecuencia Respiratoria/efectos de los fármacos , Xilazina/administración & dosificación , Xilazina/sangre , Xilazina/farmacologíaRESUMEN
The study aims to evaluate whether the analgesic effect of intra-articular (IA) route of xylazine administered to horses following arthroscopic surgery is due to a local or a systemic action. Two connected studies were performed. In the first, 1 mg/kg b.w. of xylazine was injected IA, and blood samples were taken to assess drug systemic absorption. In addition, systemic effects of the drug (sedation, ataxia or reduction of respiratory and cardiac rate) were registered. Control horses injected with saline IA were included in the study to exclude the influence of anaesthesia in the occurrence of these manifestations. In the second study, 1 mg/kg b.w. of xylazine was administered intravenously (i.v.) in healthy horses. Blood samples were collected to determine the concentrations of xylazine, and the same signs of systemic effects of the drug were recorded. By correlating these parameters, a systemic 'no effect' concentration was defined. Pharmacokinetic data after IA administration resulted in some xylazine absorption (bioavailability equal to 58.12%) with values above the systemic 'no effect' concentration. The occurrence of some signs related to systemic effects in horses receiving IA xylazine was significant compared with horses receiving saline. In conclusion, a systemic action of the drug after IA administration cannot be excluded.
Asunto(s)
Analgésicos/farmacología , Analgésicos/farmacocinética , Enfermedades de los Caballos/tratamiento farmacológico , Xilazina/farmacología , Xilazina/farmacocinética , Animales , Artroscopía/efectos adversos , Artroscopía/veterinaria , Caballos , Inyecciones Intraarticulares/veterinaria , Artropatías/cirugía , Artropatías/veterinaria , Dolor/etiología , Dolor/prevención & control , Dolor/veterinariaRESUMEN
To compare the pharmacokinetics of coadministered intraperitoneal ketamine and xylazine in young (8 to 10 wk; n = 6) and old rats (2 to 2.4 y; n = 6), blood samples obtained at 15 and 30 min and 1, 2, and 4 h after drug administration were analyzed by HPLC-tandem mass spectrometry. In both groups, the withdrawal reflex was absent during anesthesia and was present at 1.1 (± 0.2) and 2.6 (± 0.7) h after drug administration in young and old rats, respectively, with the first voluntary movement at 1.5 ± 0.2 and 4.9 ± 1.0 h. Drug availability of ketamine and xylazine was 6.0 and 6.7 times greater, respectively, in old than young rats. The rate constant of elimination of both drugs was greatly decreased and the elimination half-life was significantly greater in old compared with young rats. In conclusion, age and associated factors affect the availability of ketamine and xylazine when coadministered to attain clinical anesthesia, changing the pharmacokinetics of these drugs and prolonging anesthesia duration and recovery times with aging. Compared with their young counterparts, aged rats required much higher doses to attain a similar level of anesthesia. Finally, the long half-life of both ketamine and xylazine, when coadministered to old rats, may be a factor in research protocols because residual plasma concentrations could still be present for as long as 3 and 5 d, respectively, after administration.
Asunto(s)
Anestesia/veterinaria , Anestésicos Disociativos/farmacocinética , Hipnóticos y Sedantes/farmacocinética , Ketamina/farmacocinética , Xilazina/farmacocinética , Factores de Edad , Envejecimiento , Anestesia/métodos , Anestésicos Disociativos/sangre , Animales , Quimioterapia Combinada , Humanos , Hipnóticos y Sedantes/sangre , Ketamina/sangre , Ratas , Ratas Sprague-Dawley , Xilazina/sangreRESUMEN
OBJECTIVE: To compare the effects of xylazine on mechanical nociceptive thresholds in donkeys and horses. STUDY DESIGN: Randomized, controlled, crossover, Latin-square, operator-blinded design. ANIMALS: Six 3.1 ± 0.89 year old standard donkeys weighing 145.0 ± 30.5 kg and six 9.6 ± 4.4 year old Thoroughbred horses weighing 456.0 ± 69.0 kg. METHODS: Each animal received one of four doses of xylazine (0.5, 0.7, 0.9, and 1.1 mg kg(-1) ), or acepromazine (0.05 mg kg(-1) ) or saline solution (0.9%) intravenously and mechanical nociceptive thresholds were assessed over 90 minutes. The areas under the threshold change versus time curve values for 60 minutes (AUC(0-60) ) post-drug administration were used to compare the effect of treatment. A 1-week interval was allowed between successive trials on each animal. RESULTS: All doses of xylazine, but not acepromazine or saline, increased mechanical thresholds for up to 60 minutes. Xylazine-induced hypoalgesia was dose-dependent and corresponding AUC(0-60) values for each treatment were not significantly different between donkeys and horses (p ≥ 0.0697). CONCLUSION: The hypoalgesic effects of xylazine at four different doses were not different between donkeys and horses. CLINICAL RELEVANCE: Xylazine induced a similar degree of mechanical hypoalgesia in donkeys and horses suggesting that similar doses are needed for both species with regard to analgesia.
Asunto(s)
Analgésicos/farmacología , Equidae , Dolor/veterinaria , Xilazina/farmacología , Acepromazina/farmacocinética , Acepromazina/farmacología , Analgésicos/administración & dosificación , Analgésicos/farmacocinética , Animales , Área Bajo la Curva , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Femenino , Masculino , Dolor/prevención & control , Xilazina/administración & dosificación , Xilazina/farmacocinéticaRESUMEN
OBJECTIVE: To describe the pharmacokinetics, cortisol response and behavioral changes associated with administration of sub-anesthetic xylazine and ketamine prior to castration. STUDY DESIGN: Prospective, randomized experiment. ANIMALS: Twenty-two male beef calves (260-310 kg). METHODS: Calves were randomly assigned to receive the following treatment immediately prior to surgical or simulated castration; 1) uncastrated, placebo-treated control (CONT) (n=4),2) Castrated, placebo treated control (CAST) (n=6), 3) castrated with intravenous xylazine (X) (0.05 mg kg(-1)) (n=6), and 4) castrated with IV xylazine (X) (0.05 mg kg(-1) ) combined with ketamine (K) (0.1 mg kg(-1)) (n=6). Blood samples collected over 10 hours post-castration were analyzed by LC-MS-MS for drug concentrations and chemiluminescent immunoassay for cortisol determination. RESULTS: Drug concentrations during the first 60 minutes post-castration fit a one-compartment open model with first-order elimination. The harmonic mean elimination half-lives (± pseudo SD) for X, X with K and K were 12.9 ± 1.2, 11.2 ± 3.1 and 10.6 ± 2.8 minutes, respectively. The proportion of the total area under the effect curve (AUEC) for cortisol during this period was significantly lower in the X group (13 ± 3%; p=0.006) and the X+K group (14 ± 2%; p=0.016) compared with the CAST calves (21 ± 2%). However, after 300 minutes the AUEC in the X group was higher than CAST. Significantly more calves demonstrated attitude that was unchanged from pre-manipulation behavior in the CONT (p=0.021) and X+K treated calves (p=0.0051) compared with the CAST calves. CONCLUSIONS: Behavioral changes and lower serum cortisol concentrations during the first 60 minutes post-castration were associated with quantifiable xylazine and ketamine concentrations. CLINICAL RELEVANCE: Low doses of xylazine and ketamine administered immediately prior to castration may offer a safe, efficacious and cost-effective systemically administered alternative or adjunct to local anesthesia.
Asunto(s)
Anestesia Intravenosa/veterinaria , Ketamina/farmacología , Orquiectomía/veterinaria , Xilazina/farmacología , Anestésicos Disociativos/sangre , Anestésicos Disociativos/farmacocinética , Anestésicos Disociativos/farmacología , Animales , Bovinos , Relación Dosis-Respuesta a Droga , Hipnóticos y Sedantes/sangre , Hipnóticos y Sedantes/farmacocinética , Hipnóticos y Sedantes/farmacología , Ketamina/administración & dosificación , Ketamina/farmacocinética , Masculino , Dolor/tratamiento farmacológico , Dolor/veterinaria , Xilazina/administración & dosificación , Xilazina/farmacocinéticaAsunto(s)
Ciclosporina/farmacocinética , Inmunosupresores/farmacocinética , Ketamina/farmacocinética , Xilazina/farmacocinética , Agonistas alfa-Adrenérgicos/farmacocinética , Agonistas alfa-Adrenérgicos/farmacología , Anestésicos Disociativos/farmacocinética , Anestésicos Disociativos/farmacología , Animales , Ciclosporina/farmacología , Interacciones Farmacológicas , Inmunosupresores/farmacología , Ketamina/farmacología , Ratas , Ratas Sprague-Dawley , Xilazina/farmacologíaRESUMEN
The objective of this study was to evaluate the plasma pharmacokinetics of ketamine and its active metabolite norketamine administered intravenously at a dose of 0.1 mg/kg together with xylazine (0.05 mg/kg) to control the pain associated with castration in calves. A two-compartment model with an additional metabolite compartment linked to the central compartment was used to simultaneously describe the time-concentration profiles of both ketamine and its major metabolite norketamine. Parameter values estimated from the time-concentration profiles observed in this study were volume of the central compartment (V(c) = 132.82 +/- 68.23 mL/kg), distribution clearance (CL(D) = 15.49 +/- 2.56 mL/min/kg), volume of the peripheral compartment (V(T) = 257.05 +/- 41.65 mL/kg), ketamine clearance by the formation of the norketamine metabolite (CL(2M) = 8.56 +/- 7.37 mL/kg/min) and ketamine clearance by other routes (CL(o) = 16.41 +/- 3.42 mL/kg/min). Previously published data from rats suggest that the metabolite norketamine contributes to the analgesic effect of ketamine, with a potency that is one-third of the parent drug. An understanding of the time-concentration relationships and the disposition of the parent drug and its metabolite is therefore important for a better understanding of the analgesic potential of ketamine in cattle.
Asunto(s)
Agonistas alfa-Adrenérgicos/farmacocinética , Anestésicos Disociativos/farmacocinética , Bovinos/metabolismo , Ketamina/análogos & derivados , Ketamina/farmacocinética , Xilazina/farmacocinética , Anestesia Intravenosa/veterinaria , Anestésicos Disociativos/sangre , Animales , Bovinos/sangre , Cromatografía Liquida/veterinaria , Combinación de Medicamentos , Ketamina/sangre , Masculino , Orquiectomía/veterinaria , Dolor/tratamiento farmacológico , Dolor/veterinariaRESUMEN
The study was conducted to evaluate the effects of xylazine individually (0.05 mg/kg), ketamine individually (2.5 mg/kg), and a combination of xylazine and ketamine (0.05 mg/kg and 2.5 mg/kg) after lumbar epidural administration in water buffalo calves. Fifteen non-descript, male water buffalo calves of 6-8 months of age weighing between 55 and 75 kg were randomly placed in three groups (groups A, B and C). The agents were administered at the first lumbar epidural space. Clinico-physiological parameters, such as analgesia, ataxia, sedation, salivation, heart rate, respiratory rate and rectal temperature were studied. Other haematological and biochemical parameters monitored were haemoglobin, packed cell volume, total leukocyte count, plasma glucose, cortisol, protein albumin, globulin, blood urea nitrogen (BUN), creatinine, alanineamino transferase (ALT), sodium, potassium and chloride. The onset of analgesia (mean +/- SEM) was faster in group C (3.2 +/- 0.20 min) compared with that of group B (4.6 +/- 0.22 min) and group A (34.0 +/- 1.86 min). Analgesia of the thorax, flank, inguinal region, hind limbs, perineum and tail was complete in group C, but mild to moderate in groups A and B. Ataxia was severe in group C and mild in groups A and B. Mild to deep sedation was produced by groups A and C animals. Group B animals failed to produce sedation. Longer duration and greater depth of analgesia was produced in animals of group C. Heart rate, respiratory rate and rectal temperature decreased in groups A and C. The haematological parameters decreased in all the groups. The biochemical parameters like glucose, cortisol, BUN, creatinine, and ALT increased in all the animals. However, total proteins and albumin decreased in the three groups. The plasma electrolytes sodium, potassium and chloride did not show any significant change. The results of this study indicated a possible synergistic analgesic interaction between epidurally administered xylazine and ketamine, without causing any marked systemic effects in water buffalo calves.
Asunto(s)
Agonistas alfa-Adrenérgicos/farmacología , Analgesia Epidural/veterinaria , Analgésicos/farmacología , Búfalos/fisiología , Ketamina/farmacología , Xilazina/farmacología , Agonistas alfa-Adrenérgicos/farmacocinética , Analgesia Epidural/métodos , Analgésicos/farmacocinética , Animales , Área Bajo la Curva , Quimioterapia Combinada , Frecuencia Cardíaca/efectos de los fármacos , Ketamina/farmacocinética , Masculino , Distribución Aleatoria , Respiración/efectos de los fármacos , Resultado del Tratamiento , Xilazina/farmacocinéticaRESUMEN
The study was conducted to evaluate the effects of xylazine alone (0.05 mg/kg), lignocaine alone (2.0 mg/kg) and a combination of xylazine and lignocaine (0.05 mg/kg and 2.0 mg/kg, respectively) after lumbar epidural administration in water buffalo calves. Fifteen nondescript, male water buffalo calves of 6-8 months of age and weighing between 55 and 75 kg were randomly placed in 3 groups (A, B and C). The agents were administered at the 1st lumbar epidural space. Clinico-physiological parameters such as analgesia, ataxia, sedation, salivation, heart rate, respiratory rate and rectal temperature were studied. Other haematological and biochemical parameters monitored were haemoglobin, packed cell volume, total leukocyte count, plasma glucose, cortisol, protein albumin, globulin, blood urea nitrogen, creatinine, ALT, sodium, potassium and chloride. The onset of analgesia was faster in group C (3.0 +/- 0.44 min) compared with that of group B (4.4 +/- 0.40 min) and group A (34.0 +/- 1.86 min). Analgesia of the thorax, flank, inguinal region, hind limbs, perineum and tail was complete in group C, but mild to moderate in groups A and B. Ataxia was severe in groups B and C and mild in group A. Mild to deep sedation were produced by groups A and C animals. Longer duration and greater depth of analgesia was produced in animals in group C. Heart rate, respiratory rate and rectal temperature decreased in groups A and C. The haematological parameters decreased in all the groups. The biochemical parameters like glucose, cortisol, blood urea nitrogen, creatinine, ALT increased in all the animals. However, total proteins and albumin decreased in the 3 groups. The plasma electrolytes sodium, potassium and chloride did not show any significant change. The results of this study indicated a possible additive analgesic interaction between epidurally administered xylazine and lignocaine, without causing any marked systemic effects in water buffalo calves.
Asunto(s)
Agonistas alfa-Adrenérgicos/farmacología , Analgesia Epidural/veterinaria , Búfalos/fisiología , Lidocaína/farmacología , Xilazina/farmacología , Agonistas alfa-Adrenérgicos/farmacocinética , Analgesia Epidural/métodos , Animales , Animales Recién Nacidos , Quimioterapia Combinada , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/fisiología , Inyecciones Epidurales/veterinaria , Lidocaína/farmacocinética , Masculino , Respiración/efectos de los fármacos , Xilazina/farmacocinéticaRESUMEN
OBJECTIVE: To examine the influence of administration route on the analgesic effects of identical doses of xylazine in sheep. A prospective, linear, randomised laboratory study. PROCEDURE: The analgesic response to the administration of 2.5 mg of the alpha2 agonist xylazine either intravenously, intramuscularly or subcutaneously was assessed using an analgesia testing method based upon a learned response to a painful electrical stimulus. RESULTS: Intravenous administration achieved the most rapid onset and highest peak analgesic values of all administration methods, but was characterised by a shorter duration of action (25 min). Intramuscular and subcutaneous administration resulted in a longer duration of action (40 min) and a greater total analgesic response. CONCLUSION: For the routine management of acute pain, intramuscular administration provided the best combination of onset, duration and total analgesic response of the routes examined. The absence of adverse side effects, such as sedation, normally associated with the administration of alpha2 agonists should also encourage the use of this method as a simple and effective means of providing significant analgesia in the sheep.
Asunto(s)
Agonistas alfa-Adrenérgicos/farmacología , Agonistas alfa-Adrenérgicos/farmacocinética , Ovinos/metabolismo , Xilazina/farmacología , Xilazina/farmacocinética , Agonistas alfa-Adrenérgicos/administración & dosificación , Animales , Área Bajo la Curva , Inyecciones Intramusculares/veterinaria , Inyecciones Intravenosas/veterinaria , Inyecciones Subcutáneas/veterinaria , Dimensión del Dolor/efectos de los fármacos , Dimensión del Dolor/veterinaria , Estudios Prospectivos , Xilazina/administración & dosificaciónRESUMEN
OBJECTIVE: To quantitate the dose and time-related effects of morphine sulfate on the anesthetic sparing effect of xylazine hydrochloride in halothane-anesthetized horses and determine the associated plasma xylazine and morphine concentration-time profiles. ANIMALS: 6 healthy adult horses. PROCEDURE: Horses were anesthetized 3 times to determine the minimum alveolar concentration (MAC) of halothane in O2 and characterize the anesthetic sparing effect (ie, decrease in MAC of halothane) by xylazine (0.5 mg/kg, i.v.) administration followed immediately by i.v. administration of saline (0.9% NaCI) solution, low-dose morphine (0.1 mg/kg), or high-dose morphine (0.2 mg/kg). Selected parameters of cardiopulmonary function were also determined over time to verify consistency of conditions. RESULTS: Mean (+/- SEM) MAC of halothane was 1.05 +/- 0.02% and was decreased by 20.1 +/- 6.6% at 49 +/- 2 minutes following xylazine administration. The amount of MAC reduction in response to xylazine was time dependent. Addition of morphine to xylazine administration did not contribute further to the xylazine-induced decrease in MAC (reductions of 21.9 +/- 1.2 and 20.7 +/- 1.5% at 43 +/- 4 and 40 +/- 4 minutes following xylazine-morphine treatments for low- and high-dose morphine, respectively). Overall, cardiovascular and respiratory values varied little among treatments. Kinetic parameters describing plasma concentration-time curves for xylazine were not altered by the concurrent administration of morphine. CONCLUSIONS AND CLINICAL RELEVANCE: Administration of xylazine decreases the anesthetic requirement for halothane in horses. Concurrent morphine administration to anesthetized horses does not alter the anesthetic sparing effect of xylazine or its plasma concentration-time profile.
Asunto(s)
Adyuvantes Anestésicos/farmacología , Anestesia por Inhalación/veterinaria , Anestésicos por Inhalación/administración & dosificación , Halotano/administración & dosificación , Morfina/farmacología , Xilazina/metabolismo , Adyuvantes Anestésicos/farmacocinética , Análisis de Varianza , Anestésicos por Inhalación/metabolismo , Animales , Análisis de los Gases de la Sangre , Presión Sanguínea , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas/fisiología , Halotano/metabolismo , Frecuencia Cardíaca , Caballos , Morfina/farmacocinética , Xilazina/farmacocinéticaRESUMEN
Xylazine hydrochloride was administered i.m. at 0.35 mg/kg to 13 steers and 10 lactating dairy cows at Time 0. Ten minutes later, tolazoline hydrochloride was given i.v. at 4 mg/kg. Tissue and milk samples were analyzed using gas chromatography with nitrogen and phosphorous detection to determine concentrations of xylazine, 2,6-dimethylaniline (a toxic metabolite of xylazine), and tolazoline (at various intervals). Concentrations of xylazine and 2,6- dimethylaniline were below the limit of quantitation (10 microg/kg) by 72 hours in tissues and 12 hours in milk. The concentration of tolazoline was below 10 microg/kg by 96 hours in tissues and 48 hours in milk. Based on the results of these residue studies submitted by the sponsoring agency to the Ministry of Agriculture and Forestry in New Zealand, withholding periods for both xylazine hydrochloride and tolazoline hydrochloride injection were established.
Asunto(s)
Agonistas alfa-Adrenérgicos/farmacocinética , Antagonistas Adrenérgicos alfa/farmacocinética , Compuestos de Anilina/farmacocinética , Bovinos/metabolismo , Leche/metabolismo , Tolazolina/farmacocinética , Xilazina/farmacocinética , Agonistas alfa-Adrenérgicos/administración & dosificación , Agonistas alfa-Adrenérgicos/sangre , Antagonistas Adrenérgicos alfa/administración & dosificación , Antagonistas Adrenérgicos alfa/sangre , Compuestos de Anilina/sangre , Animales , Industria Lechera , Residuos de Medicamentos/metabolismo , Femenino , Hipnóticos y Sedantes/administración & dosificación , Hipnóticos y Sedantes/antagonistas & inhibidores , Infusiones Intravenosas/veterinaria , Inyecciones Intramusculares/veterinaria , Riñón/metabolismo , Hígado/metabolismo , Músculo Esquelético/metabolismo , Distribución Aleatoria , Tolazolina/administración & dosificación , Tolazolina/sangre , Xilazina/administración & dosificación , Xilazina/sangreRESUMEN
This study was performed to clarify the antagonistic actions of intravenous or epidural atipamezole on the sedative and analgesic effects of xylazine administered between the epidural fat and dura mater through the first interlumbar space in cattle. Cattle received 5 mL of a solution containing 0.05 mg x kg(-1) xylazine in 0.9% saline. Thirty minutes later, 5 mL of 0.9% saline was administered through the same needle (treatment 1) (XSE). In treatments 2 (XAE) and 3 (XAV), 5 mL of a solution containing 0.025 mg x kg(-1) atipamezole in 0.9% saline was administered epidurally or intravenously, respectively. Sedation and analgesia were similar in all three treatment groups and could be reversed by atipamezole given by either route. In the XAV treatment, the flank area relapsed into analgesia 25+/-5.8 min following reversal of the analgesic effect, and was maintained for 112.5+/-63.8 min. The present study confirmed that the sedative and analgesic effects of xylazine are completely reversed by atipamezole and can be influenced by the epidural fat in cattle. Furthermore, it seems probable that analgesia following epidural administration of xylazine is mediated by alpha(2)-adrenergic receptors, not by a local anaesthetic effect.